

Information Governance

13 June 2018

Our Ref: RFI 23437

Dear

**Freedom of Information Act 2000
Information in Relation to Metastatic Squamous Cell Non-small Cell Lung
Cancer (NSCLC)**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 9 May 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Catherine Treanor
Information Governance Assistant**

I have a Freedom of Information request, within your Trust in the last 3 months – latest that you have available;

Metastatic Squamous Cell Non-small cell lung cancer (NSCLC):

In the past 3 months, how many patients were treated with

| | |
|---|---|
| <i>Atezolizumab (Tecentriq)</i> | 0 |
| <i>Pembrolizumab (Keytruda)</i> | 0 |
| <i>Nivolumab (Opdivo)</i> | 0 |
| <i>Other active systemic anti-cancer therapy</i> | 5 patients have started chemotherapy in last 3 months |
| <i>Palliative care only</i> | This information is not centrally held. Please see comment below. |

Given the breadth of palliative care and the multiple settings that this patient group is managed across it would take in excess of 18 hours to collate this information.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

Metastatic Non Squamous Cell Non-small cell lung cancer (NSCLC):

In the past 3 months, how many patients were treated with

| | |
|---|---|
| <i>Atezolizumab (Tecentriq)</i> | 0 |
| <i>Pembrolizumab (Keytruda)</i> | 0 |
| <i>Nivolumab (Opdivo)</i> | 0 |
| <i>Other active systemic anti-cancer therapy</i> | <5 patients have started chemotherapy in last 3 months |
| <i>Palliative care only</i> | This information is not centrally held. Please see comment below. |

Given the breadth of palliative care and the multiple settings that this patient group is managed across it would take in excess of 18 hours to collate this information.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

Adjuvant Melanoma

In the past three months how many patients were seen who had stage III resectable melanoma?

There were less than 5 patients diagnosed between 1 January 2018 and 31 March 2018.

Of all stage III patients seen, how many received a complete resection?

Less than five were offered resection.

Of all stage III patients seen, how many were stage III a?

This information is not centrally recorded.